Swiss Heart Foundation   Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: Bern Switzerland (1967)

Organization Overview

First Clinical Trial
2004
NCT00596479
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Swiss Heart Foundation

Active Ingredients

Drugs in Phase 4 Trials (2)

laropiprant (1 trial)

niacin (1 trial)

Drugs in Phase 3 Trials (1)

colchicine (colbenemid) (1 trial)

Drugs in Phase 2 Trials (1)

68ga-nodaga-rgd (1 trial)

Drugs in Other Trials (2)

oxygen (1 trial)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 4)

Carotid Artery Diseases (Phase 2)

Inflammation (Phase 2)

Plaque, Atherosclerotic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 6